WO2023204291A1 - ビシクロアミンカルボキサミド誘導体 - Google Patents
ビシクロアミンカルボキサミド誘導体 Download PDFInfo
- Publication number
- WO2023204291A1 WO2023204291A1 PCT/JP2023/015863 JP2023015863W WO2023204291A1 WO 2023204291 A1 WO2023204291 A1 WO 2023204291A1 JP 2023015863 W JP2023015863 W JP 2023015863W WO 2023204291 A1 WO2023204291 A1 WO 2023204291A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkoxy
- same
- substituted
- different halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention provides a therapeutic or preventive drug for diseases involving orexin receptors, particularly orexin type 2 receptors, which contains a novel compound having a fused ring skeleton or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a therapeutic or preventive drug for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea syndrome.
- Orexin is a neuropeptide that is specifically produced in specific nerve cells scattered in the lateral hypothalamic area of the brain and its surrounding areas.
- Orexin is an endogenous ligand of orexin receptor, which is a G protein-coupled receptor mainly present in the brain, and binds to orexin receptor.
- orexin receptors Two subtypes of orexin receptors, type 1 and type 2, are known (Non-Patent Document 1).
- Non-Patent Document 2 It has been reported that narcolepsy-like symptoms that occur in transgenic mice with degenerated orexin neurons are improved by intracerebroventricular administration of orexin peptide (Non-Patent Document 2), and knockout of prepro-orexin, a precursor protein of orexin ( It has also been reported that narcolepsy-like symptoms are induced by KO) (Non-Patent Document 3), and it has also been revealed that the orexin concentration in the cerebrospinal fluid of narcolepsy patients is significantly reduced (Non-Patent Document 3). Patent Document 4) suggested that narcolepsy is caused by orexin deficiency.
- Non-patent Document 5 mutations in orexin type 2 receptors have been reported in dogs with hereditary narcolepsy (Non-patent Document 5), suggesting that orexin type 2 receptors are involved in sleep-wakefulness, and furthermore, KO of orexin type 2 receptors has been reported. It has been revealed that narcolepsy-like symptoms are also induced in mice (Non-Patent Document 6), and the involvement of orexin type 2 receptor stimulation in the wakefulness maintenance effect is strongly suggested. against this background, orexin type 2 receptor agonists are expected to be promising therapeutic agents for diseases exhibiting hypersomnia symptoms such as narcolepsy.
- Patent Document 1 or 2 compounds having orexin type 2 receptor agonist activity have been reported.
- An object of the present invention is to provide therapeutic or preventive agents for diseases involving orexin type 2 receptors, specifically narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, and other diseases. It is in.
- the present inventors found that the compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof (hereinafter sometimes referred to as "the compound of the present invention”)
- the present invention has therapeutic and preventive effects on diseases involving type 2 receptors, specifically narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea syndrome. reached.
- the present invention is as follows.
- R 3 and R 4 each independently represent a hydrogen atom or an optionally substituted C 1-4 alkyl;
- R 5 represents optionally substituted C 1-4 alkyl;
- R a4 and X 3 may be bonded together; however, when both R a4 and X 3 are CR a4 , the two R a4s and the carbon atoms bonded to them both form a 5-membered ring constituted by X 1 , X 2 and X 3 may form a 6-membered carbon ring fused with] ]
- a compound represented by or a pharmaceutically acceptable salt thereof may be bonded together; however, when both R a4 and X 3 are CR a4 , the two R a4s and the carbon atoms bonded to them both form a 5-membered ring constituted by X 1 , X 2 and X 3 may form a 6-membered carbon ring fused with] ]
- a compound represented by or a pharmaceutically acceptable salt thereof A compound represented by or a pharmaceutically acceptable salt thereof.
- each substitutable group in “optionally substituted C 1-4 alkyl” is independently one or more of the same or different halogen atom, hydroxy group, C 1- 4 alkoxy or C 3-7 cycloalkyl, and each substitutable group in “optionally substituted C 1-4 alkoxy” is independently one or more of the same or different halogen atoms, is a hydroxy group or C 3-7 cycloalkyl,
- Substitutable substituents in the C 6-10 aromatic carbocyclic group, 5- to 10-membered aromatic heterocyclic group, C 3-6 saturated carbocyclic group, and 4- to 10-membered saturated heterocyclic group of ring G are , each independently a halogen atom, C 1-6 alkyl (the alkyl is substituted with one or more of the same or different halogen atoms, hydroxy group, C 1-4 alkoxy, or C 3-7 cycloalkyl) ), C 6-10 aromatic carbocyclic group (
- the substitutable groups in "optionally substituted C 1-4 alkyl" in R 1 to R 7 are each independently one or more of the same or different halogen atoms or C 1-4 alkoxy; , each substitutable group in “optionally substituted C 1-4 alkoxy” is independently one or more of the same or different halogen atoms, Substitutable substituents in the C 6-10 aromatic carbocyclic group, 5- to 10-membered aromatic heterocyclic group, C 3-6 saturated carbocyclic group, and 4- to 10-membered saturated heterocyclic group of ring G are , each independently a halogen atom, C 1-6 alkyl (the alkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkoxy), C 6-10 aromatic carbocyclic group (the C 6-10 aromatic carbocyclic group may be substituted with one or more of the same or different halogen atoms, C 1-4 alkyl, or C 1-4 alkoxy), C
- Ring E is represented by the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3), or (1a- 3-4):
- X 1 to X 5 each independently represent a nitrogen atom or -CR a4 -;
- R a1 to R a4 each independently (if there is a plurality of CR a4 , each R a4 also independently) represents a hydrogen atom, a halogen atom, a C 6-10 aromatic carbocyclic group (the C 6 -10 aromatic carbocyclic group may be substituted with one or more of the same or different halogen atoms, hydroxy group, C 1-4 alkyl, or C 1-4 alkoxy), C 1-4 alkyl ( The alkyl may be substituted with one or more of the same or different halogen atoms, hydroxy groups, or C 1-4 alkoxy), C 3-7 cycloalkyl (the cycloalkyl may be substituted with one or
- Ring G is the following formula (1b-1) or (1b-2): [In the formula, W 1 and W 3 each independently represent a nitrogen atom or -CR b3 -; W 2 and W 4 each independently represent -NR b4 -, an oxygen atom, or -CR b5 R b6 -; R b1 to R b6 each independently represent a hydrogen atom, -N(R b7 )R b8 , C 1-6 alkyl (the alkyl is one or more of the same or different halogen atoms, C 3-6 cyclo alkyl (the cycloalkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkyl, and the C 1-4 alkyl may be substituted with a halogen atom), or may be substituted with C 1-4 alkoxy), C 6-10 aromatic carbocyclic group (the C 6-10 aromatic carbocyclic group may be substituted with one or more same or
- R b1 and R b2 may be bonded via C 1-6 alkylene to form any chemically possible bicyclic structure among fused rings, spiro rings, and bridged rings.
- R b7 and R b8 each independently represent a hydrogen atom, C 1-6 alkyl (the alkyl is one or more of the same or different halogen atoms, C 1-4 alkoxy, C 3-7 cycloalkyl)
- Cycloalkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkyl, and the C 1-4 alkyl may be substituted with a halogen atom), or 5 to 10 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with one or more of the same or different halogen atoms, C 1-4 or C 3-7 cycloalkyl (the cycloalkyl may be substituted with one or more of the same or different
- R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a C 1-4 alkyl (the alkyl is one or more of the same or different halogen atoms, a hydroxy group, a C 1-4 alkoxy, or a C 1-4 alkyl).
- R 6 is each independently a hydrogen atom or C 1-4 alkyl (the alkyl is one or more of the same or different halogen atoms, a hydroxy group, C 1-4 alkoxy, or C 3-7 cycloalkyl); may be substituted);
- Ring G has the following formula (1b-1) or (1b-2): [In the formula, W
- R b7 and R b8 each independently represent a hydrogen atom, C 1-6 alkyl (the alkyl is one or more of the same or different halogen atoms, C 1-4 alkoxy, C 3-7 cycloalkyl) Cycloalkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkyl, and the C 1-4 alkyl may be substituted with a halogen atom), or 5 to 10 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with one or more of the same or different halogen atoms, C 1-4 or C 3-7 cycloalkyl (the cycloalkyl may be substituted with one or more of the same or different halogen atoms, hydroxy group, C 1-4 alkyl, or optionally substituted with C 1-4 alkoxy),
- R b1 to R b6 are -N(R b7 )R b8 , R b7
- a 1 represents an oxygen atom or a sulfur atom
- j, k, l, and m are each independently an integer of 0, 1, or 2
- the dashed line portion represents a single bond or a double bond
- X represents -CR 7 -, a nitrogen atom, or a carbon atom
- R 7 is a hydrogen atom, a hydroxy group, a halogen atom, cyano, or a C 1-4 alkyl (the alkyl is one or more of the same or different halogen atoms, a hydroxy group, a C 1-4 alkoxy, or a C 3- (optionally substituted with 7 cycloalkyl);
- Ring E is represented by the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3), or (1a- 3-4): [In the formula, X 1 to X 5 each independently represent a nitrogen atom or -CR a4 -; R a1 to R a4 each
- R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a C 1-4 alkyl (the alkyl is one or more of the same or different halogen atoms, a hydroxy group, a C 1-4 alkoxy, or a C 1-4 alkyl (optionally substituted with 3-7 cycloalkyl); L 1 represents a single bond or an oxygen atom; Ring G is the following formula (1b-1-1), (1b-2-1), (1b-1-2), or (1b-2-2): [In the formula, R b4 , R b7 , and R b8 are each independently a hydrogen atom or C 1-6 alkyl (the alkyl is one or more of the same or different halogen atoms or C 1-4 alkoxy ) may be substituted]
- Ring E is the above formula (1a-2-1) or (1a-3-1): [In the formula, X 4 to X 5 each independently represent a nitrogen atom or -CR a4 -; R a1 to R a4 are each independently (if there is a plurality of CR a4 , each R a4 is also independently) a hydrogen atom, a halogen atom, a C 1-4 alkyl (the alkyl is 1 or 2 C 3-7 cycloalkyl (which may be substituted with one or more of the same or different halogen atoms or C 1-4 alkoxy), C 3-7 cycloalkyl (the cycloalkyl may be substituted with one or more of the same or different halogen atoms, a hydroxy group, C 1-4 alkoxy), -4 alkyl or C 1-4 alkoxy), or C 1-4 alkoxy (the alkoxy may be substituted with one or more of the same or different halogen atoms)
- Ring E is the following formula (1a-2-2) or (1a-3-1): [In the formula, R a1 to R a3 are each independently a hydrogen atom, a halogen atom, a C 1-4 alkyl (the alkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkoxy); or C 3-7 cycloalkyl (the cycloalkyl may be substituted with one or more of the same or different halogen atoms, hydroxy group, C 1-4 alkyl, or C 1-4 alkoxy) ]
- Ring G has the following formula (1b-1-1) or (1b-2-1): [Wherein, R b4 represents a hydrogen atom or C 1-6 alkyl (the alkyl may be substituted with one or more of the same or different halogen atoms or C 1-4 alkoxy)] represents; R 7 is a hydrogen atom or C 1-4 alkyl (even if the alkyl is substituted with one or more of the same or different halogen atoms, hydroxy group, C 1-4 alkoxy, or C 3-7 cycloalkyl) good); Ring E is represented by the following formula (1a-2-2) or (1a-3-1): [In the formula, R a1 to R a3 are each independently a hydrogen atom, a halogen atom, a C 1-4 alkyl (the alkyl is substituted with one or more of the same or different halogen atoms or C 1-4 al
- Ring G represents the above formula (1b-1-1), and R b4 is C 1-4 alkyl which may be substituted with one or more of the same or different halogen atoms. or a pharmaceutically acceptable salt thereof.
- Ring G represents the above formula (1b-2-1), and R b4 is a hydrogen atom or C 1-4 alkyl (the alkyl is one or more of the same or different halogen atoms or C 1-4 alkoxy 13.
- Item 17 A therapeutic agent for a disease associated with orexin type 2 receptor, comprising a compound according to any one of Items 1 to 16 or a pharmaceutically acceptable salt thereof.
- Kleiner-Levin syndrome major depression associated with hypersomnia, Lewy body dementia
- Dementia Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Mobius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated cerebrospinal coma, loss of consciousness, obesity (e.g., malignant mast cells, extrinsic obesity, hyperinsulinic obesity, hyperplasmic obesity, Pituitary obesity, hypoplasma obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, dietary obesity, hypogonadal obesity, systemic mastocytosis, simple obesity, central obesity), insulin resistance syndrome, Alzheimer's disease, disorders of consciousness such as coma, side effects and complications due to anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal clonic muscle spasms, REM Sleep disruption,
- the risk of secondary outcomes of obesity such as decreased risk of hypercholesterolemia, hyperuricemia, lower back pain, gallbladder disease, gout, kidney cancer, left ventricular hypertrophy, migraines, headaches, neurological Pathogenic pain, Parkinson's disease, psychosis, schizophrenia, hot flushes, night sweats, genital/urinary system disorders, disorders related to sexual function or fertility, dysthymia disorder, bipolar disorder, bipolar I disorder, bipolar II disorder disorders, cyclothymia disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attacks, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorders, heart bypass surgery and transplantation.
- obesity such as decreased risk of hypercholesterolemia, hyperuricemia, lower back pain, gallbladder disease, gout, kidney cancer, left ventricular hypertrophy, migraines, headaches, neurological Pathogenic pain, Parkinson's disease, psychosis, schizophrenia, hot flushes
- Acute neurological and psychiatric disorders such as post-cerebral deficits, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neurological injury, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasms, tremors, epilepsy, disorders associated with muscle spasms, delirium, amnestic disorders, age-related Cognitive decline, schizoaffective disorder, delusional disorder, drug dependence, dyskinesia, chronic fatigue syndrome, fatigue, medication-induced parkinsonism, Gilles de la Tourette syndrome, chorea, myoclonus, tics, restless lower extremity syndrome , dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), conduct disorder, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinopathy, ma
- a therapeutic agent for narcolepsy comprising a compound according to any one of Items 1 to 16 or a pharmaceutically acceptable salt thereof.
- a therapeutic agent for idiopathic hypersomnia comprising a compound according to any one of Items 1 to 16 or a pharmaceutically acceptable salt thereof.
- narcolepsy idiopathic hypersomnia, comprising administering to a patient in need of treatment a therapeutically effective amount of the compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof;
- Treatment and/or of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with Lewy body dementia A compound according to any one of Items 1 to 16 or a pharmaceutically acceptable salt thereof for use in prophylaxis.
- a drug containing a compound or a pharmaceutically acceptable salt thereof according to any one of Items 1 to 16 for treating narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, or narcolepsy-like symptoms.
- the number of carbon atoms in the definition of “substituent” may be expressed as, for example, “C 1-6 ".
- C 1-6 alkyl is synonymous with alkyl having 1 to 6 carbon atoms.
- substituents that do not specifically specify the term “optionally substituted” or “substituted” mean “unsubstituted” substituents.
- C 1-6 alkyl means “unsubstituted C 1-6 alkyl.”
- substituents in this specification may be omitted.
- the number of substituents when present is not particularly limited as long as they can be substituted, and is one or more. That is, it indicates that the corresponding group may be substituted with a substitutable number of substituents on a substitutable carbon atom or a carbon atom and a nitrogen atom.
- the description of each group also applies when the group is a part or substituent of another group.
- halogen examples include fluorine, chlorine, bromine, and iodine. Preferably it is fluorine or chlorine.
- C 1-4 alkyl means a linear or branched saturated hydrocarbon group having 1 to 4 carbon atoms
- C 1-6 alkyl means a saturated hydrocarbon group having 1 to 4 carbon atoms. It means 6 straight or branched saturated hydrocarbon groups.
- Specific examples of “C 1-4 alkyl” include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl
- specific examples of “C 1-6 alkyl” include the above-mentioned In addition to pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, and structural isomers thereof.
- the "C 1-6 alkyl” or “C 1-4 alkyl” is preferably methyl, ethyl, propyl, or isopropyl, and more preferably methyl or isopropyl.
- C 1-6 alkylene means a straight or branched divalent saturated hydrocarbon group having 1 to 6 carbon atoms.
- C 1-6 alkylene preferably “C 1-4 alkylene” is mentioned, and more preferably “C 1-3 alkylene” is mentioned.
- Specific examples of “C 1-3 alkylene” include methylene, ethylene, propylene, trimethylene and the like.
- Specific examples of “C 1-4 alkylene” include butylene, 1,1-dimethylethylene, 1,2 -dimethylethylene, 1 -methyltrimethylene, 2-methyltrimethylene and the like.
- C 1-6 alkylene include pentylene, 1,1-dimethyltrimethylene, 1,2-dimethyltrimethylene, in addition to those listed as specific examples of “C 1-4 alkylene” above. , 1-methylbutylene, 2-methylbutylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene, hexylene, and the like.
- C 3-7 cycloalkyl means a cyclic non-aromatic hydrocarbon group (saturated hydrocarbon group and partially unsaturated hydrocarbon group) having 3 to 7 carbon atoms. Preferably it is “C 3-6 cycloalkyl”. “C 3-7 cycloalkyl” also includes crosslinked ones. Specific examples of “C 3-7 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, cycloheptyl, and the like.
- C 3-7 cycloalkyl has one, or the same or different, hetero atom selected from “C 3-7 cycloalkyl” and a benzene ring or 5- or 6-membered nitrogen, sulfur or oxygen.
- a bicyclic group fused with two or more (for example, 2 to 4) rings for example, a 5- or 6-membered ring among the "4- to 10-membered saturated heterocycles” described below is also included. Included.
- C 1-4 alkoxy means an oxy group substituted with the above “C 1-4 alkyl”
- C 1-6 alkoxy means an oxy group substituted with the above “C 1-6 alkyl”.
- Specific examples of “C 1-4 alkoxy” include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc.
- Specific examples of “C 1-6 alkoxy” include , in addition to those listed as specific examples of “C 1-4 alkoxy", pentyloxy, hexyloxy and the like can be mentioned.
- “C 1-4 alkoxy” or “C 1-6 alkoxy” is preferably methoxy, ethoxy or isopropoxy.
- C 3-7 cycloalkoxy means an oxy group substituted with the above-mentioned “C 3-7 cycloalkyl". Preferably it is “C 3-6 cycloalkoxy”. Specific examples of “C 3-7 cycloalkoxy” include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like. Preferably it is cyclohexyloxy.
- C 6-10 aromatic carbocyclic group is an aromatic hydrocarbon group having 6 to 10 carbon atoms, and is also referred to as "C 6-10 aryl.” Specific examples of the “C 6-10 aromatic carbocyclic group” include phenyl, 1-naphthyl, 2-naphthyl, and the like. More preferred is phenyl.
- the "C 6-10 aromatic carbocyclic group” contains "phenyl” and one hetero atom selected from nitrogen, sulfur, or oxygen, or two or more (for example, 2 to 4) of the same or different heteroatoms.
- a 5- or 6-membered ring for example, a 5- or 6-membered monocyclic aromatic heterocyclic group described below, a 5- or 6-membered 4- to 10-membered saturated heterocycle described below
- groups fused with a 5- to 7-membered cycloalkyl ring eg, cyclopentane, cyclohexane, or cycloheptane are also included.
- a 5- to 10-membered aromatic heterocyclic group means, in addition to carbon atoms constituting the ring, one or more heteroatoms selected from nitrogen, sulfur, or oxygen, or two or more of the same or different heteroatoms (e.g. means a monocyclic or polycyclic 5- to 10-membered aromatic group containing 2 to 4). Preferably, it is a "5- or 6-membered monocyclic aromatic heterocyclic group".
- “5- or 6-membered monocyclic aromatic heterocyclic group” means a monocyclic 5- or 6-membered aromatic group among "5- to 10-membered aromatic heterocyclic group”.
- the polycyclic aromatic heterocyclic group in the above-mentioned "5- to 10-membered aromatic heterocyclic group” is a condensation of two identical or different monocyclic aromatic heterocycles, or a monocyclic aromatic heterocyclic group.
- Examples include those in which an aromatic heterocycle of the formula formula is condensed with an aromatic ring (eg, benzene, etc.) or a non-aromatic ring (eg, cyclohexane, etc.).
- the "5- to 10-membered aromatic heterocyclic group” include pyrazolyl, imidazolyl, benzofuranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and the like.
- preferred examples include benzofuranyl (bond position is on the heteroaryl (furan) ring), pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl.
- C 3-6 saturated carbocycle means a monocyclic saturated or partially unsaturated hydrocarbon ring having 3 to 6 carbon atoms.
- Specific examples of "C 3-6 saturated carbocycle” include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene, and the like.
- cyclopropane or cyclobutane is used.
- “4- to 10-membered saturated heterocycle” means, in addition to carbon, the atoms constituting the ring include one or more same or different atoms selected from the group consisting of oxygen atoms, nitrogen atoms, and sulfur atoms (e.g. , 2 to 4, preferably 2 to 3, more preferably 2) heteroatoms, a monocyclic or bicyclic saturated heterocycle consisting of 4 to 10 atoms. , those having a partially unsaturated bond, those having a partially crosslinked structure, and those having a partially spiroated structure. Preferably it is a 5- or 6-membered saturated heterocycle.
- the bicyclic saturated heterocycle also includes a condensed monocyclic saturated heterocycle with benzene or a monocyclic 5- to 6-membered aromatic heterocycle.
- the saturated heterocycle may contain one or two carbonyl, thiocarbonyl, sulfinyl or sulfonyl, for example, lactam, thiolactam, lactone, thiolactone, cyclic imide, cyclic carbamate, Cyclic groups such as cyclic thiocarbamates are also included in the saturated heterocycle.
- the oxygen atom of carbonyl, sulfinyl, and sulfonyl and the sulfur atom of thiocarbonyl are not included in the number of 4 to 10 members (ring size) and the number of heteroatoms constituting the ring.
- the "4- to 10-membered saturated heterocycle” preferably includes a monocyclic or bicyclic "4- to 8-membered saturated heterocycle," and more preferably a monocyclic "4- to 6-membered saturated heterocycle.” A monocyclic "5- or 6-membered saturated heterocycle" is more preferred.
- the "4- to 10-membered saturated heterocycle” include piperazine, oxetane, azetidine, pyrrolidine, pyrazolidine, imidazolidine, piperidine, morpholine, homopiperidine, thiomorpholine, dioxothiomorpholine, hexamethyleneimine, oxazolidine, Examples include thiazolidine, oxoimidazolidine, dioxoimidazolidine, oxooxazolidine, dioxooxazolidine, dioxothiazolidine, tetrahydrofuran, tetrahydropyran, and tetrahydropyridine.
- bicyclic saturated heterocycles include indoline, isoindoline, dihydropurine, dihydrothiazolopyrimidine, dihydrobenzodioxane, dihydroindazole, dihydropyrrolopyridine, tetrahydroquinoline, decahydroquinoline, tetrahydroisoquinoline, decahydroisoquinoline. , tetrahydronaphthyridine, tetrahydropyridazepine, and the like.
- 4- to 6-membered saturated heterocyclic group means a substituent in which "4- to 6-membered saturated heterocycle” is a monovalent group among the above “4- to 10-membered saturated heterocycle” do.
- Preferred examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl.
- the compounds of the present invention also include various hydrates, solvates, and crystal polymorphs.
- the compounds of the present invention may also be substituted with isotopic elements (e.g., D, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 35 S, 18 F , 125 I, etc.). These compounds are also included in the compounds of the present invention.
- isotopic elements e.g., D, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 35 S, 18 F , 125 I, etc.
- the compounds of the present invention also include all tautomers, all existing stereoisomers, and mixtures thereof.
- the optically active form of the compound of the present invention can be produced by using an optically active starting material or by optically resolving the final racemic form.
- optical resolution methods include physical separation methods using optically active columns and chemical separation methods such as fractional crystallization.
- “pharmaceutically acceptable salts” refer to acid addition salts and base addition salts that are pharmaceutically acceptable.
- pharmaceutically acceptable salts include, but are not limited to, acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, Citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonic acid, paratoluenesulfonate (tosylate), lauryl sulfate, malate, ascorbate, mandelate, saccharate, xinafoate, pamoate, cinnamate, adipate, cysteine salt, N-acetyl cysteine salt , hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide
- the compound of the present invention can be administered orally or parenterally, either directly or after being made into a preparation, medicament, or pharmaceutical composition using an appropriate dosage form.
- dosage forms include, but are not limited to, tablets, capsules, powders, granules, solutions, suspensions, injections, patches, poultices, and the like.
- these preparations can be manufactured by known methods using additives that are commonly used as pharmaceutical additives.
- these additives include excipients, disintegrants, binders, fluidizing agents, lubricants, coating agents, solubilizers, solubilizers, thickeners, dispersants, and stabilizers. , sweeteners, flavoring agents, etc. can be used.
- specific examples of these additives include, but are not limited to, lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, and hydroxyl.
- examples include propylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, and talc.
- the dosage of the compound of the present invention is appropriately selected depending on the animal to be administered, the route of administration, the disease, and the age, weight, and symptoms of the patient.
- the lower limit is 0.01 mg and the upper limit is 10,000 mg per day for adults, and this amount can be administered once a day or divided into several doses.
- the compound of the present invention is a compound that has agonistic activity on orexin type 2 receptor. Therefore, it can be a useful therapeutic or preventive agent for diseases involving orexin type 2 receptors. Specific examples of these diseases include narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and dementia with Lewy bodies.
- Hypersomnia hypersomnia syndrome with excessive daytime sleep (e.g., Kleine-Levin syndrome, major depression with excessive sleep, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prada-Willi syndrome, Möbius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis, Wernicke's encephalitis, limbic encephalitis, Hashimoto's encephalopathy), coma, loss of consciousness, obesity (e.g., Kleine-Levin syndrome, major depression with excessive sleep, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prada-Willi syndrome, Möbius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction
- malignant mast cells extrinsic obesity, hyperinsulinemic obesity, hyperplasma obesity, pituitary obesity, hypoplasma obesity, hypothyroid obesity, Hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, dietary obesity, hypogonadal obesity, systemic mastocytosis, simple obesity, central obesity), insulin resistance syndrome, Alzheimer's, coma disturbances of consciousness such as anesthesia, side effects and complications due to anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal clonic muscle spasms, REM sleep interruption, jet lag, jet lag syndrome, sleep disorders in shift workers , sleep abnormalities, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's twilight syndrome, diseases related to circadian rhythms, fibromyalgia, conditions resulting from poor sleep quality, overeating , compulsive eating disorders, obesity-related diseases, hypertension, diabetes, increased plasma insulin levels and insulin resistance, hyperlipidemia, hyperlipidemia, endometri
- obesity hypoventilation syndrome Pieris
- respiratory diseases such as dyspnea
- inflammation such as systemic inflammation of the vascular system
- arteriosclerosis such as arteriosclerosis
- hypercholesterolemia such as hypercholesterolemia
- hyperuricemia lower back pain
- gallbladder disease the risk of secondary outcomes of obesity, such as lowering the risk of gout, kidney cancer, left ventricular hypertrophy, migraines, headaches, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, hot flushes, and night sweats.
- diseases of the genital/urinary system diseases related to sexual function or fertility, dysthymia disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymia disorder, acute stress disorder, agoraphobia, generalized anxiety acute neurological and psychiatric disorders, such as obsessive-compulsive disorder, panic attacks, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorders, cerebral deficits after heart bypass surgery and transplantation; Stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorders related to muscle spasm, delirium, amnestic disorder, age-related cognitive decline, schizoaffective disorder, delusional disorder, drug dependence, movement abnormalities chronic fatigue syndrome, fatigue
- Preferred examples include narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with Lewy body dementia.
- the compound of the present invention is a compound that has agonistic activity on orexin type 2 receptor. Therefore, it can be a useful therapeutic or prophylactic agent for diseases involving orexin type 2 receptors.
- the compounds of the present invention are particularly effective against a group of sleep-wake disorders, specific examples of which include insomnia disorder, hypersomnia disorder, narcolepsy, narcolepsy without cataplexy but with orexin (hypocretin) deficiency, Narcolepsy with cataplexy but without orexin (hypocretin) deficiency, autosomal dominant cerebellar ataxia with deafness and narcolepsy, autosomal dominant narcolepsy with obesity and type 2 diabetes, narcolepsy secondary to other medical conditions, respiratory Related sleep disorders, circadian rhythm sleep-wake disorders, parasomnias, restless legs syndrome, substance/drug-induced sleep disorders, other specified insomnia disorders, unspecified insomnia Hypersomnia Disorder, Other Specified Hypersomnia
- prevention refers to the act of administering the compound of the present invention to a healthy person who has not developed a disease, and is aimed, for example, at preventing the onset of a disease.
- Treatment is the act of administering the compound of the present invention to a person (patient) who has been diagnosed by a doctor as having developed a disease, for example, to alleviate the disease or symptoms or to prevent the onset of the disease. The purpose is to return to the state of Furthermore, even if the purpose of administration is to prevent the worsening of a disease or symptom, if it is administered to a patient, it is considered a therapeutic act.
- the compound of the present invention is a therapeutic agent for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or a therapeutic agent for Parkinson's disease or Lewy body dementia.
- diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, and narcolepsy syndrome with narcolepsy-like symptoms include, for example, amphetamine, methylphenidate, modafinil, armodafinil, and sodium oxybate.
- Parkinson's disease or Lewy body dementia examples include levodopa, carbidopa, entacapone, MAOB inhibitors (e.g., zonisamide, selegiline, rasagiline, safinamide, etc.), dopamine receptor agonists (e.g., bromocriptine, pergolide, talipexole, etc.).
- MAOB inhibitors e.g., zonisamide, selegiline, rasagiline, safinamide, etc.
- dopamine receptor agonists e.g., bromocriptine, pergolide, talipexole, etc.
- the administration period of the compound of the present invention and the concomitant drug is not limited, and they may be administered to the subject at the same time or at different times. It may also be used as a combination of the compound of the present invention and a concomitant drug.
- the dosage of the concomitant drug can be appropriately selected based on the clinically used dosage. Further, the compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the subject of administration, administration route, target disease, symptoms, combination, etc.
- the compound of the present invention may be synthesized by a combination of the production method shown below and a known synthesis method.
- Each of the compounds in the reaction formula may form a salt, and examples of the salt include the same salts as the above-mentioned "pharmaceutically acceptable salts". It should be noted that these reactions are merely illustrative, and the compounds of the present invention can also be produced by other methods as appropriate based on the knowledge of those skilled in organic synthetic chemistry.
- the desired product may be obtained by deprotection after completion of the reaction or after a series of reactions.
- protecting group for example, the literature (T. W. Greene and P. G. M. Wuts, ⁇ Protective Groups in Organic Synthesis'', 3rd Ed., John Wiley and Sons, inc., New York (1999) ) etc. can be used. More specifically, as protecting groups for amino groups, for example, tert-butoxycarbonyl, benzyloxycarbonyl, p-toluenesulfonyl, o-nitrobenzene, etc. can be used.
- protective groups for carboxyl groups include acetal, etc., and examples include tert-butyl ester, orthoester, and amide.
- protecting groups can be carried out using methods commonly used in organic synthetic chemistry (for example, T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons , inc., New York (1999)) or a method similar thereto.
- Manufacturing method 1 The compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be produced, for example, by the following production method. (In the formula, R 1 , R 2 , L 1 , j, k, l, m, n, ring G, A 1 , the broken line part, X, and ring E have the same meanings as in term 1.)
- Process (1-1) Compound (s-1-1) is produced by subjecting compound (s-1-2) and compound (s-1-3) to a reaction under commonly used urea bond forming conditions in an appropriate inert solvent. be able to. Conditions for this reaction include, for example, conditions using triphosgene, 4-nitrophenylchloroformate, 1,1'-carbonyldiimidazole, or thiophosgene. A base is used in this reaction, and examples of the base used include triethylamine, diisopropylethylamine, and the like.
- inert solvents examples include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, methyl acetate, etc.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF, and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ethyl acetate methyl acetate
- ester solvents examples include ester solvents.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- step (1-1) the intermediate isocyanate etc. may be isolated and the subsequent conversion may be performed.
- Manufacturing method 2 Among the compounds represented by formula (s-1-2), the compound represented by formula (s-2-1) can be produced, for example, by the following manufacturing method.
- R 7 , R a1 , Q 2 , j, k, l and m have the same meanings as in term 1.
- P 1 represents a suitable protecting group, and has the same meaning even if there is no explanation below.
- Compound (s-2-4) can be produced by subjecting compound (s-2-2) and compound (s-2-3) to a reaction under commonly used addition reaction conditions in an appropriate inert solvent.
- inert solvents include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, and alcohols such as methanol and ethanol.
- solvents and water The reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- Compound (s-2-6) can be produced by subjecting compound (s-2-4) and compound (s-2-5) to a reaction under commonly used condensation reaction conditions in an appropriate inert solvent. Can be done. Conditions for this reaction include, for example, conditions using HATU, DCC, or CDI. In this reaction, a base is used depending on the case, and examples of the base used include triethylamine and diisopropylethylamine.
- solvents include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, methyl acetate, and the like.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF, and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ethyl acetate methyl acetate
- ester solvents examples include ester solvents.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- Compound (s-2-7) can be produced by subjecting compound (s-2-6) to a reaction under commonly used dehydration reaction conditions in an appropriate inert solvent.
- a base such as triethylamine or DBU may be used depending on the case.
- inert solvents include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, and acetic acid.
- ester solvents such as methyl.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- Compound (s-2-1) can be obtained by preparing compound (s-2-7) by a known method (for example, Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, written by R. C. Larocque). et al., VCH publisher Inc., 1989).
- the compound represented by formula (s-3-1) can be produced, for example, by the following method.
- R a2 , R a3 , X 6 , X 7 , X 8 , j, k, l, and m have the same meanings as in term 1.
- M represents a metal such as lithium or magnesium halide.
- Z represents boronic acid, boronic acid ester, BF 3 K, BF 3 Na, trialkyltin, zinc halide, or hydrogen atom, and Y represents halogen.
- Compound (s-3-1) can be synthesized from compound (s-3-2) through steps (3-1) to (3-3).
- Compound (s-3-4) can be obtained by combining compound (s-3-2) and compound (s-3-3) in an appropriate inert solvent under conditions without additives or in the presence of a Lewis acid. It can be produced by subjecting a ketone to addition reaction conditions.
- the Lewis acid used in this reaction include zinc (II) chloride, scandium triflate (III), copper (I) chloride, boron trifluoride, boronic acid, and boronic acid ester.
- the inert solvent examples include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF and 1,4-dioxane, and aromatic hydrocarbon solvents such as benzene, toluene and xylene.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene and xylene.
- Compound (s-3-5) can be produced by subjecting compound (s-3-4) to a reaction under commonly used dehydration reaction conditions in an appropriate inert solvent.
- the dehydration reaction conditions include conditions using a dehydrating agent such as an acid or Burgess reagent, conditions such as Mitsunobu reaction, or converting a hydroxyl group into a leaving group (through methanesulfonylation, p-toluenesulfonylation, or halogen substitution, etc.). These are conditions for performing an elimination reaction using a base or the like after conversion.
- acids used in this reaction include protic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, zinc chloride (II), scandium triflate (III), and copper chloride.
- protic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, zinc chloride (II), scandium triflate (III), and copper chloride.
- protic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, zinc chloride (II), scandium triflate (III), and copper chloride.
- boron trifluoride such as boronic acid esters, and the like.
- Examples of the base used in this reaction include organic bases such as triethylamine, diisopropylethylamine, or DBU, inorganic bases such as sodium bicarbonate, sodium carbonate, and potassium carbonate, metal alkoxides such as tert-butoxypotassium, n-butyllithium, etc.
- organic bases such as triethylamine, diisopropylethylamine, or DBU
- inorganic bases such as sodium bicarbonate, sodium carbonate, and potassium carbonate
- metal alkoxides such as tert-butoxypotassium, n-butyllithium, etc.
- organometallic reagents such as isopropylmagnesium chloride, metal amide reagents such as LDA and LHMDS, and the like.
- inert solvents examples include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, and acetic acid.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF, and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ethyl acetate examples include acetic acid.
- ester solvents such as methyl.
- the reaction time is usually about 1 to 24 hours, and the reaction temperature is from -78°C to the boiling point of the solvent.
- Process (3-3) Compound (s-3-1) can be produced using compound (s-3-5) under the same conditions as step (2-4).
- Compound (s-3-5) can also be synthesized from compound (s-3-2) through step (3-4) and step (3-5).
- Process (3-4) Compound (s-3-6) can be reacted with a commonly used triflating agent in an appropriate inert solvent in the absence of additives or in the presence of an acid or a base (or in the simultaneous presence of an acid and a base). It can be produced by subjecting compound (s-3-2) to a reaction.
- the triflating agent used in this reaction include trifluoromethanesulfonic anhydride and N-phenylbis(trifluoromethanesulfonimide).
- the acid used in this reaction include Lewis acids such as zinc (II) chloride, scandium triflate (III), copper (I) chloride, boron trifluoride, boronic acid, and boronic acid ester.
- Examples of the base used in this reaction include organic bases such as triethylamine, diisopropylethylamine, or DBU, inorganic bases such as sodium bicarbonate, sodium carbonate, and potassium carbonate, metal alkoxides such as tert-butoxypotassium, n-butyllithium, etc.
- organic bases such as triethylamine, diisopropylethylamine, or DBU
- inorganic bases such as sodium bicarbonate, sodium carbonate, and potassium carbonate
- metal alkoxides such as tert-butoxypotassium, n-butyllithium, etc.
- organometallic reagents such as isopropylmagnesium chloride, metal amide reagents such as LDA and LHMDS, and the like.
- inert solvents examples include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, and acetic acid.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF, and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ethyl acetate examples include acetic acid.
- ester solvents such as methyl.
- the reaction time is usually about 1 to 24 hours, and the reaction temperature is from -78°C to the boiling point of the solvent.
- Compound (s-3-5) can be prepared by preparing compound (s-3-6) in an appropriate inert solvent in the presence of a palladium catalyst and a phosphine ligand, if necessary. It is produced by reacting with a compound (s-3-7) in which Z is represented by boronic acid, boronic acid ester, BF 3 K, BF 3 Na, trialkyltin, or zinc halide in the presence of a base.
- Compound (s-3-7) can be purchased as a commercial product, or synthesized by a known method or a method analogous thereto.
- palladium catalysts examples include tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), and bis(tri-tert-butylphosphine)palladium.
- (0) palladium acetate (0), [1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) etc.
- phosphine ligand examples include o-tolylphosphine, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos), and 2-dicyclohexylphosphino-2',4',6'-triisopropyl.
- Biphenyl 1,1'-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane ( DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 4,5-bis(diphenylphosphino) -9,9-dimethylxanthene (XANT-Phos), bis(2-(diphenylphosphino)phenyl)ether (DPE-Phos), and the like.
- DPPF 1,1'-bis(diphenylphosphino)ferrocene
- DPPE 1,2-bis(diphenylphosphino)ethane
- DPPP 1,3-bis(diphenylphosphino)propane
- Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, potassium hydroxide, and the like.
- Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and mixed solvents thereof.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- Compound (s-3-5) can also be synthesized from compound (s-3-2) through step (3-6) and step (3-7).
- the conditions for the vinyl halide production reaction used in this reaction are, for example, conditions in which hydrazine is reacted and then tetramethylguanidine and iodine are reacted, phosphorous acid and bromine are reacted in the presence of triethylamine, or conditions in which phosphorous pentachloride and trichloride are reacted. Examples include conditions under which a chlorinating reagent such as phosphorus chloride is allowed to act.
- inert solvents examples include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, and acetic acid.
- halogenated carbons such as chloroform and dichloromethane
- ether solvents such as diethyl ether, THF, and 1,4-dioxane
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ethyl acetate examples include acetic acid.
- ester solvents such as methyl.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -78°C to the boiling point of the solvent.
- Process (3-7) Compound (s-3-5) can be produced using compound (s-3-8) under the same conditions as step (3-5).
- Manufacturing method 4 Among the compounds represented by formula (s-1-2), the compound represented by formula (s-4-1) can be produced, for example, by the following manufacturing method. (In the formula, R a2 , R a3 , X 6 , X 7 , X 8 , j, k, l and m have the same meanings as in term 1.)
- Compound (s-4-1) can be obtained from compound (s-3-5) through step (4-1) and step (4-2), or from compound (s-3-1) through step (4-2). It can be synthesized through 3).
- Process (4-1) Compound (s-4-2) can be synthesized by compound (s-4-2) under commonly used double bond reduction reaction conditions in an appropriate inert solvent or, if necessary, in a hydrogen atmosphere, without additives, or in the presence of an acid.
- s-3-5) can be produced by subjecting it to a reaction. Conditions for this reaction include, for example, conditions using palladium on carbon, palladium (II) hydroxide, or Raney nickel, and conditions using a hydride reducing agent such as triethylsilane.
- acids used in this reaction include protonic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
- inert solvents include halogenated carbons such as chloroform and dichloromethane, ether solvents such as diethyl ether, THF, and 1,4-dioxane, aromatic hydrocarbon solvents such as benzene, toluene, and xylene, ethyl acetate, and acetic acid.
- ester solvents such as methyl
- alcohol solvents such as methanol and ethanol.
- Process (4-2) Compound (s-4-1) can be produced using compound (s-4-2) under the same conditions as step (2-4).
- Process (4-3) Compound (s-4-1) can be produced using compound (s-3-1) under the same conditions as step (4-1).
- Manufacturing method 5 Among the compounds represented by formula (s-1-2), the compound represented by formula (s-5-1) can be produced, for example, by the following manufacturing method. (In the formula, R a2 , R a3 , X 6 , X 7 , X 8 , j, k, l and m have the same meanings as in term 1. Also, Y represents halogen.)
- Compound (s-5-1) can be synthesized from compound (s-5-2) through step (5-1) and step (5-2).
- Compound (s-5-4) is prepared by preparing compound (s-5-2) in an appropriate inert solvent in the presence of a palladium catalyst, a phosphine ligand, and a base. -5-3).
- Compound (s-5-3) can be purchased as a commercial product, or synthesized by a known method or a method analogous thereto.
- palladium catalysts include tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), and bis(tri-tert-butylphosphine)palladium.
- phosphine ligand examples include o-tolylphosphine, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos), and 2-dicyclohexylphosphino-2',4',6'-triisopropyl.
- Biphenyl 1,1'-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane ( DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 4,5-bis(diphenylphosphino) -9,9-dimethylxanthene (XANT-Phos), bis(2-(diphenylphosphino)phenyl)ether (DPE-Phos), and the like.
- DPPF 1,1'-bis(diphenylphosphino)ferrocene
- DPPE 1,2-bis(diphenylphosphino)ethane
- DPPP 1,3-bis(diphenylphosphino)propane
- Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, potassium hydroxide, and the like.
- Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and mixed solvents thereof.
- the reaction time is usually about 1 hour to 24 hours, and the reaction temperature is from -20°C to the boiling point of the solvent.
- step (5-1) when compound (s-5-3) is a compound in which an aromatic nucleophilic substitution reaction proceeds, compound (s-5-2) and compound (s- Compound (s-5-4) can also be synthesized by reacting 5-3).
- Process (5-2) Compound (s-5-1) can be produced using compound (s-5-4) under the same conditions as step (2-4).
- Rt Retention time min: min
- HATU O-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
- DCC N,N'-Dicyclohexylcarbodiimide
- CDI Carbonyldiimidazole
- THF Tetrahydrofuran
- TFA Trifluoroacetic acid
- DMSO Dimethyl sulfoxide Boc: tert-butoxycarbonyl
- DBU Diazabicycloundecene
- LDA Lithium diisopropylamide
- LHMDS Lithium bis(trimethylsilyl) Amide
- silica gel columns and amino columns manufactured by Yamazen Co., Ltd. were used.
- Silica gel 60F254 Merck
- TLC plate NH Fluji Silysia
- Method B Solvent: Solution A; 0.05% TFA/H 2 O, Solution B; Acetonitrile Gradient conditions: 0.0-1.7 minutes (linear gradient from B 10% to B 99%), 1.7-1.9 minutes (B 99%), 1.9-3.0 Minutes (B 10%) Flow rate: 0.5 mL/min; detection UV: 254 nm; temperature: 40°C
- Example 1 (3aR,5S,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N- ⁇ (1R,6S)-2,2-difluoro-6-[4 -(propan-2-yl)piperazin-1-yl]cyclohexyl ⁇ hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide
- Example 2 shown in the table below was prepared in the same manner as in Example 1 using the known literature products or reference examples listed in the table below as compounds corresponding to raw material A and raw material B described in Example 1. ⁇ 17 compounds were prepared.
- Example 2 (3aR,5S,6aS)-N- ⁇ (1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl ⁇ -5- ⁇ 5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl ⁇ hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide
- Example 3 (1R,5S,6R)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N- ⁇ (1R,6S)-2,2-difluoro-6-[4 -(Propan-2-yl)piperazin-1-yl]cyclohexyl ⁇ -3-azabicyclo[3.1.0]hexane-3-carboxamide
- Example 4 (1R,5S,6aS)-N- ⁇ (1R,6S)-2,
- Example 5 and Example 10 are diastereomixtures containing two different diastereomers. These can also be isolated by asymmetric synthesis or chiral chromatography. That is, it can be said that the two diastereomers were substantially synthesized.
- Example 18 shown in the table below was prepared in the same manner as in Example 1, using the known literature products or reference examples listed in the table below as compounds corresponding to raw material A and raw material B described in Example 1. ⁇ 34 compounds were prepared.
- Example 18 (3aR,6aS)-N- ⁇ (1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl ⁇ -5-(4 -fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide
- Example 19 (3aR,6aS)-N- ⁇ (1R,6S)-2,2-difluoro-6-[ 4-(Propan-2-yl)piperazin-1-yl]cyclohexyl ⁇ -5-(2-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide
- Example 20 (3aR ,6aS)-N- ⁇ (1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]
- Reference examples 5 to 11 In place of cyclopropanecarboxylic acid in step (ii) in Reference Example 4, using carboxylic acid B listed in the table below, Synthesize Reference Example 5 shown in the table below according to the method described in Reference Example 4 above, Further, in place of the raw material (compound 2) in step (i) and the cyclopropanecarboxylic acid in step (ii) in Reference Example 4, corresponding raw materials A and carboxylic acid B were used, and the method described in Reference Example 4 was carried out. Compounds of Reference Examples 6 to 11 shown in the table below were synthesized according to the following.
- Reference Example 5 (3aR,5s,6aS)-5- ⁇ 5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl ⁇ octahydrocyclopenta[ c] Pyrrole
- Reference Example 6 (1R,5S,6r)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[3.1.0]hexane Hydrochloride
- Reference Example 7 (1R,5S,6s)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[3.1.0]hexane monohydrochloride Salt
- Reference Example 8 (1S,6R,8S)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[4.2.0]octane monohydrochloride Reference Example
- Reference examples 13 to 16 In place of 4-methylphenylboronic acid in step (i) in Reference Example 12, the compounds of Reference Examples 13 to 16 shown in the table below were prepared according to the method described in Reference Example 12 above, using the corresponding raw material C. Synthesized.
- Reference Example 13 (3aR,5r,6aS)-5-(2-methylphenyl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference Example 14 (3aR,5r,6aS)-5-(4-fluorophenyl ) Octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference Example 15 (3aR,5r,6aS)-5-(3-fluorophenyl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference Example 16 (3aR, 5r,6aS)-5-(2-fluorophenyl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference example 17 (3aR,6aS)-2-(2-fluorophenyl)octahydropyrrolo[3,4-c]pyrrole monohydrochloride
- Reference example 18 (3aR,6aS)-2-(3-fluorophenyl)octahydropyrrolo[3,4-c]pyrrole monohydrochloride Instead of 1-bromo-2-fluorobenzene in step (i) in Reference Example 17, 1 Using -bromo-3-fluorobenzene, the compound of Reference Example 18 shown in the table below was synthesized according to the method described in Reference Example 17 above.
- Reference example 19 (3aR,5r,6aS)-5-(3-methylphenyl)octahydrocyclopenta[c]pyrrole monohydrochloride Instead of 4-methylphenylboronic acid in step (i) in Reference Example 12, 3-methylphenyl Using boronic acid, the compound of Reference Example 19 shown in the table below was synthesized according to the method described in Reference Example 12 above.
- Reference example 20 (3aR,5r,6aS)-5-(pyridin-2-yl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Ferrocene] dichloropalladium (II) (278 mg) and 1,1'-bis(diphenylphosphino)ferrocene (189 mg) were added at room temperature, and the mixture was stirred at 80°C for 8 hours. After cooling to room temperature, the reaction mixture was filtered through Celite and washed with ethyl acetate.
- Reference examples 21 and 22 In place of 2-bromopyridine in step (ii) in Reference Example 19, the corresponding raw materials D were used to synthesize the compounds of Reference Examples 21 and 22 shown in the table below according to the method described in Reference Example 19 above. .
- Reference Examples 21 and 22 The compound names of Reference Examples 21 and 22 are listed below.
- Reference example 21 (3aR, 5r, 6aS)-5-(pyrimidin-2-yl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference example 22 (3aR, 5r, 6aS)-5-(pyridine-3 -yl) octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference example 23 (3aR,5r,6aS)-5-(5-methyl-1,2,4-oxadiazol-3-yl)octahydrocyclopenta[c]pyrrole monohydrochloride
- Reference Example 23 shown in the table below was carried out according to the method described in Reference Example 4 above, using the compound of Reference Example 1 in place of (Compound 2), the cyclopropanecarboxylic acid in step (ii), and acetyl chloride in place of HATU. The compound was synthesized.
- Test Example 1 Measurement of orexin type 2 receptor agonist activity Human orexin type 2 receptor and apoaequorin were transiently expressed in CHO cells, and agonism was evaluated using the amount of calcium flowing into the cells upon ligand stimulation as an index. .
- the transiently expressed cells were seeded in a 384-well plate at 2,000 cells/well and cultured for 16 to 22 hours. After returning the plate to room temperature, add Coelenterazine hcp (final concentration: 1 ⁇ M) and let it stand at room temperature for 2 hours. Then, add Orexin A (Peptide Institute Co., Ltd., Lot. 671009) or the test compound and add Coelenterazine hcp (final concentration: 1 ⁇ M).
- the amount of luminescence of the cells was measured using the following method. Note that Orexin A and the test compound were dissolved in DMSO (final concentration 0.1%) and diluted with buffer (Hanks, 20mM HEPES, 0.1% BSA). In addition, the orexin type 2 receptor agonism of the test compound was calculated as a relative value, with the luminescence value upon treatment with Orexin A (100 pM) taken as 100%.
- Test results As a result of measuring the orexin type 2 receptor agonism of the compounds obtained in the examples, it was observed that the compounds of the present invention exhibit agonistic effects on the orexin type 2 receptor.
- the table below shows the relative values of the orexin type 2 receptor agonism of the compounds obtained in Examples at 10 ⁇ M, with the luminescence value upon treatment with Orexin A (100 pM) taken as 100%.
- Test Example 2 Measurement of orexin type 2 receptor agonist activity Human orexin type 2 receptor and apoaequorin were transiently expressed in CHO cells, and agonism was evaluated using the amount of calcium flowing into the cells upon ligand stimulation as an index. .
- the transiently expressed cells were seeded in a 384-well plate at 2,000 cells/well and cultured for 16 to 22 hours. After returning the plate to room temperature, add Coelenterazine hcp (final concentration: 1 ⁇ M) and let it stand at room temperature for 2 hours. Then, add Orexin A (Peptide Research Institute, Lot. 711101) or the test compound, and add Coelenterazine hcp (final concentration: 1 ⁇ M).
- the amount of luminescence of the cells was measured using the following method. Note that Orexin A and the test compound were dissolved in DMSO (final concentration 0.1%) and diluted with buffer (Hanks, 20mM HEPES, 0.1% BSA). In addition, the orexin type 2 receptor agonism of the test compound was calculated as a relative value, with the luminescence value upon treatment with Orexin A (100 pM) taken as 100%.
- Test results As a result of measuring the orexin type 2 receptor agonism of the compounds obtained in the examples, it was observed that the compounds of the present invention exhibit agonistic effects on the orexin type 2 receptor.
- the table below shows the relative values of the orexin type 2 receptor agonism of the compounds obtained in Examples at 10 ⁇ M, with the luminescence value upon treatment with Orexin A (100 pM) taken as 100%.
- the compounds of the present invention exhibit strong agonistic activity against orexin type 2 receptors, and are associated with narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, and Parkinson's disease. It is useful as a therapeutic or preventive drug for diseases such as hypersomnia and hypersomnia associated with Lewy body dementia.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202380035368.9A CN119053606A (zh) | 2022-04-22 | 2023-04-21 | 双环胺甲酰胺衍生物 |
| IL316360A IL316360A (en) | 2022-04-22 | 2023-04-21 | The origin of bicycloamine carboxamide |
| CA3248959A CA3248959A1 (en) | 2022-04-22 | 2023-04-21 | BICYCLOAMINE CARBOXAMIDE DERIVATIVE |
| JP2024516324A JPWO2023204291A1 (cg-RX-API-DMAC7.html) | 2022-04-22 | 2023-04-21 | |
| AU2023256391A AU2023256391A1 (en) | 2022-04-22 | 2023-04-21 | Bicycloamine carboxamide derivative |
| EP23791939.4A EP4512807A4 (en) | 2022-04-22 | 2023-04-21 | BICYCLOAMINE CARBOXAMIDE DERIVATIVE |
| MX2024012992A MX2024012992A (es) | 2022-04-22 | 2024-10-21 | Derivado de carboxamida bicicloamina |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022071112 | 2022-04-22 | ||
| JP2022-071112 | 2022-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023204291A1 true WO2023204291A1 (ja) | 2023-10-26 |
Family
ID=88419943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/015863 Ceased WO2023204291A1 (ja) | 2022-04-22 | 2023-04-21 | ビシクロアミンカルボキサミド誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4512807A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023204291A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053606A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023256391A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248959A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316360A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012992A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202404962A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023204291A1 (cg-RX-API-DMAC7.html) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007025069A2 (en) * | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
| WO2017135306A1 (en) | 2016-02-04 | 2017-08-10 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
| WO2021107023A1 (ja) | 2019-11-27 | 2021-06-03 | 大日本住友製薬株式会社 | シクロアルキルウレア誘導体 |
| WO2022250108A1 (ja) * | 2021-05-26 | 2022-12-01 | 住友ファーマ株式会社 | フェニルウレア誘導体 |
-
2023
- 2023-04-21 CA CA3248959A patent/CA3248959A1/en active Pending
- 2023-04-21 WO PCT/JP2023/015863 patent/WO2023204291A1/ja not_active Ceased
- 2023-04-21 CN CN202380035368.9A patent/CN119053606A/zh active Pending
- 2023-04-21 IL IL316360A patent/IL316360A/en unknown
- 2023-04-21 AU AU2023256391A patent/AU2023256391A1/en active Pending
- 2023-04-21 JP JP2024516324A patent/JPWO2023204291A1/ja active Pending
- 2023-04-21 TW TW112114914A patent/TW202404962A/zh unknown
- 2023-04-21 EP EP23791939.4A patent/EP4512807A4/en active Pending
-
2024
- 2024-10-21 MX MX2024012992A patent/MX2024012992A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007025069A2 (en) * | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
| WO2017135306A1 (en) | 2016-02-04 | 2017-08-10 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
| WO2021107023A1 (ja) | 2019-11-27 | 2021-06-03 | 大日本住友製薬株式会社 | シクロアルキルウレア誘導体 |
| WO2022250108A1 (ja) * | 2021-05-26 | 2022-12-01 | 住友ファーマ株式会社 | フェニルウレア誘導体 |
Non-Patent Citations (11)
| Title |
|---|
| "Latest Drug Discovery Chemistry: From Exploratory Research to Development", 1 January 1998, TECHNOMIC CO., LTD. , JP , ISBN: 4-924746-59-2, article WERMUTH, C.G.: "Part III Fundamentals of structure-activity relationship research: Chapter 14 Transformation of ring structures", pages: 273 - 296, XP009550335 * |
| BRAIN, vol. 130, 2007, pages 1577 - 1585 |
| CELL, vol. 92, 1998, pages 573 - 585 |
| CELL, vol. 98, 1999, pages 365 - 376 |
| NEURON, vol. 38, 2003, pages 715 - 730 |
| NEUROSCIENCE LETTERS, vol. 569, 2014, pages 68 - 73 |
| PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654 |
| R. C. LAROCK: "Comprehensive Organic Transformation", 1989, VCH PUBLISHER INC. |
| See also references of EP4512807A4 |
| T. FV GREENEP. G. M. JF,UTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
| THE LANCET, vol. 355, 2000, pages 39 - 40 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023256391A1 (en) | 2024-11-14 |
| JPWO2023204291A1 (cg-RX-API-DMAC7.html) | 2023-10-26 |
| TW202404962A (zh) | 2024-02-01 |
| CA3248959A1 (en) | 2025-02-03 |
| EP4512807A1 (en) | 2025-02-26 |
| EP4512807A4 (en) | 2026-04-08 |
| MX2024012992A (es) | 2024-11-08 |
| CN119053606A (zh) | 2024-11-29 |
| IL316360A (en) | 2024-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115003655B (zh) | 环烷基脲衍生物 | |
| JP2023134729A (ja) | 光学活性なアザビシクロ環誘導体 | |
| JP4445504B2 (ja) | Dpp−iv阻害剤としてのヘキサヒドロピリドイソキノリン | |
| EP4329877B1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| CN117561238A (zh) | 苯基脲衍生物 | |
| JP2018522847A (ja) | 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類 | |
| JP7454520B2 (ja) | 光学活性なアザビシクロ環誘導体からなる医薬 | |
| JP2024520395A (ja) | 置換される縮合二環式大環状化合物および関連のある治療方法 | |
| JPWO2020032105A1 (ja) | 光学活性な架橋型ピペリジン誘導体 | |
| JP7825294B2 (ja) | Nlrp3阻害剤としての化合物 | |
| JP6976248B2 (ja) | (r)−1−(4−(6−(2−(4−(3,3−ジフルオロシクロブトキシ)−6−メチルピリジン−2−イル)アセトアミド)ピリダジン−3−イル)−2−フルオロブチル)−n−メチル−1h−1,2,3−トリアゾール−4−カルボキサミドの塩形態および多形体 | |
| WO2018196747A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂与应用 | |
| KR20250043464A (ko) | 2(1h)-피리딘이민 유도체 | |
| JPH05262766A (ja) | ピペリジルメチル−置換クロマン誘導体 | |
| CN119053606A (zh) | 双环胺甲酰胺衍生物 | |
| HK40114399A (en) | Bicycloamine carboxamide derivative | |
| WO2018052065A1 (ja) | 複素環アミド化合物 | |
| CA3199269A1 (en) | Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| JP7668768B2 (ja) | シクロアルキルウレア誘導体を含有する医薬組成物 | |
| JP2025521504A (ja) | 置換縮合二環式化合物および関連する治療方法 | |
| HK40102586A (en) | Phenyl urea derivative | |
| HK40074199B (zh) | 环烷基脲衍生物 | |
| HK40074199A (en) | Cycloalkyl urea derivative | |
| JP2004256498A (ja) | ピロロカルバゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23791939 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 316360 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024516324 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: P2024-02759 Country of ref document: AE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2024/012992 Country of ref document: MX Ref document number: 202380035368.9 Country of ref document: CN |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024021781 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 815894 Country of ref document: NZ Ref document number: AU2023256391 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2023256391 Country of ref document: AU Date of ref document: 20230421 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202447089024 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024134350 Country of ref document: RU Ref document number: 2023791939 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023791939 Country of ref document: EP Effective date: 20241122 |
|
| ENP | Entry into the national phase |
Ref document number: 112024021781 Country of ref document: BR Kind code of ref document: A2 Effective date: 20241021 |